Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAZOBONE: first-line pazopanib in untreated metastatic renal cell carcinoma with bone involvement
2017-003706-40Phase 4Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pazopanib in renal cell carcinoma (RCC), clear cell renal cell carcinoma (ccRCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Started Nov 2020; status: terminated.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2017-003706-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003706-40.